OBSERVATIONAL CLINICAL STUDY AND PATIENT ENROLLMENT

Monitoring continues at the active centers participating in the observational clinical study (Niguarda Hospital in Milan, Bergamo Hospital, and Villa Beretta in Varese), with promising progress. Following the enrollment of the first patient on July 17 at Niguarda, two additional patients have joined the study—one at Niguarda and one at Bergamo—bringing the total number of enrolled patients to three.

All patients participating in the observational study will be monitored over the next 12 months, with the aim of collecting neurophysiological data and parameters useful for the design of the subsequent interventional study involving REMaST® cell therapy, which is scheduled to begin in 2025.

PARTICIPATION IN INTERNATIONAL CONFERENCES

In the fourth quarter of 2023, significant progress was made in defining, implementing, and validating crucial reagents not commercially available for the clinical production of REMaST®. The initial results of REMaST® development were presented and discussed at several conferences, providing valuable opportunities for exchange, networking, and learning.

We participated in “Promoting Innovation in Life Sciences,” a two-day event featuring plenary sessions, parallel sessions, exhibition spaces, and networking opportunities, held at the Trieste Convention Center on November 8 and 9. This event was a key opportunity to present our work to numerous investors.

Additionally, we were invited to the annual meeting of the British Society of Toxicological Pathology, hosted by the multinational company Evotec in Verona on November 15 and 16, 2023, titled “Preclinical Translatability and Pathology of Cell-Based Therapies.”